文献速递慢性肾脏病遗传性与小管间质肾病

晚期CKD无力型骨病因鉴别指导骨质疏松治疗

Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment.
PubMed 文献 · Kidney Int · 2021-06-05

本文综述晚期CKD(G4-5D)无力型骨病的病理生理概念,探讨低骨转换对抗骨质疏松药物安全性和疗效的影响。文章指出抗骨吸收药物在晚期CKD的使用受限于缺乏大型临床试验和对肾功能恶化及无力型骨病的担忧,但新证据表明药物或手术降低骨转换未增加死亡或血管钙化风险,慢性炎症、氧化应激、营养不良和糖尿病等导致低骨转换的因素可能与不良预后相关。

要点

  • 低骨密度可预测包括晚期CKD在内的各期CKD骨折风险。
  • 抗骨吸收药物在晚期CKD的安全性和疗效尚缺乏大型临床试验证据。
  • 降低骨转换的药物或手术未显示增加死亡或血管钙化风险。

核心结论

  • 导致骨转换抑制的病理状态而非低骨转换本身可能解释其与不良预后的关联。

主要发现

  • 低骨密度可预测所有CKD阶段包括晚期CKD(G4-5D)的骨折风险。
  • 药理学治疗可改善中度CKD的骨密度并降低骨折风险,但在晚期CKD的疗效尚待确定。
  • 近几十年来无力型骨病已成为肾性骨营养不良的最主要形式,常与过早死亡和血管钙化进展等不良结局相关。
  • 不断演变的证据表明,通过甲状旁腺切除术或拟钙剂、抗骨吸收药物等降低骨转换与过早死亡或加速血管钙化无关。
  • 慢性炎症、氧化应激、营养不良和糖尿病可诱导低骨转换并与不良预后相关。

临床怎么用

  • 临床决策时应鉴别导致无力型骨病的具体病因,而非仅关注低骨转换本身。
  • 对晚期CKD患者使用抗骨质疏松药物需权衡安全性证据的局限性。

局限性

  • 晚期CKD缺乏大型临床试验证据。
  • 合成代谢治疗在晚期CKD的安全性不确定性较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic kidney disease (CKD) have an increased fracture risk because of impaired bone quality and quantity. Low bone mineral density predicts fracture risk in all CKD stages, including advanced CKD (CKD G4-5D). Pharmacological therapy improves bone mineral density and reduces fracture risk in moderate CKD. Its efficacy in advanced CKD remains to be determined, although pilot studies suggest a positive effect on bone mineral density. Currently, antiresorptive agents are the most commonly prescribed drugs for the prevention and therapy of osteoporosis. Their use in advanced CKD has been limited by the lack of large clinical trials and fear of causing kidney dysfunction and adynamic bone disease. In recent decades, adynamic bone disease has evolved as the most predominant form of renal osteodystrophy, commonly associated with poor outcomes, including premature mortality and progression of vascular calcification. Evolving evidence indicates that reduction of bone turnover by parathyroidectomy or pharmacological therapies, such as calcimimetics and antiresorptive agents, are not associated with premature mortality or accelerated vascular calcification in CKD. In contrast, chronic inflammation, oxidative stress, malnutrition, and diabetes can induce low bone turnover and associate with poor prognosis. Thus, the conditions causing suppression of bone turnover rather than the low bone turnover per se may account for the perceived association with outcomes. Anabolic treatment, in contrast, has been suggested to improve turnover and bone mass in patients with advanced CKD and low bone turnover; however, uncertainty about safety even exceeds that of antiresorptive agents. Here, we critically review the pathophysiological concept of adynamic bone disease and discuss the effect of low bone turnover on the safety and efficacy of anti-osteoporosis pharmacotherapy in advanced CKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Haarhaus M, Evenepoel P. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int. 2021. PMID: 34102219. doi:10.1016/j.kint.2021.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。